文献速递妇产影像儿科影像技术与安全US

全基因组染色体微阵列分析在低风险妊娠中检出高比例拷贝数变异

Universal chromosomal microarray analysis reveals high proportion of copy-number variants in low-risk pregnancies.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-04-05

本研究回顾性分析2013年11月至2018年12月共6431例遗传学检测时超声正常的低风险妊娠与1326例超声异常高风险妊娠的产前染色体微阵列分析结果,低风险组临床显著早发型疾病相关拷贝数变异检出率为1.1%(72/6431),显著低于高风险组的4.9%(65/1326)。低风险组中0.4%(27/6431)为致病性或可能致病性拷贝数变异,另0.7%(45/6431)为外显率超过10%的易感位点;低风险组携带临床显著早发型拷贝数变异的妊娠中31.9%(23/72)终止妊娠,26.4%(19/72)结局数据缺失,16.7%(12/72)在遗传学检测后于孕后期发现超声异常。

要点

  • 遗传学检测时超声正常的低风险妊娠中,临床显著早发型疾病相关拷贝数变异检出率为1.1%(72/6431)。
  • 低风险妊娠中致病性或可能致病性拷贝数变异为0.4%(27/6431),外显率超过10%的易感位点为0.7%(45/6431)。
  • 低风险组中16.7%(12/72)在遗传学检测后于孕后期才发现超声异常。

核心结论

  • 低风险妊娠中检出临床显著早发型异常染色体微阵列分析结果的风险虽低于高风险妊娠,但风险仍可观,应将此风险告知所有孕妇。

研究设计与样本

  • 本研究为回顾性研究,回顾本中心2013年11月至2018年12月所有产前染色体微阵列分析结果。
  • 低风险组为遗传学检测时超声正常的妊娠,共6431例;高风险组为超声异常的妊娠,共1326例。

关键影像表现/征象

  • 低风险组中16.7%(12/72)在遗传学检测后于孕后期发现超声异常。

诊断标准与关键数值

  • 临床显著拷贝数变异定义为与早发型疾病相关的致病性或可能致病性拷贝数变异,或外显率超过10%的疾病易感位点。
  • 低风险组临床显著早发型疾病相关拷贝数变异检出率为1.1%(72/6431),高风险组为4.9%(65/1326)。
  • 低风险组致病性或可能致病性拷贝数变异为0.4%(27/6431),外显率超过10%的易感位点为0.7%(45/6431)。

临床应用与阅片要点

  • 低风险妊娠中临床显著早发型拷贝数变异检出率为1.1%(72/6431),作者认为该风险可观并应告知所有孕妇。
  • 低风险组中16.7%(12/72)在遗传学检测后于孕后期发现超声异常,提示遗传学检测后仍需继续超声随访。

局限性

  • 低风险组中26.4%(19/72)的妊娠结局数据缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the yield and utility of the routine use of chromosomal microarray analysis (CMA) for prenatal genetic diagnosis in a large cohort of pregnancies with normal ultrasound (US) at the time of genetic testing, compared with pregnancies with abnormal US findings.

METHODS: We reviewed all prenatal CMA results in our center between November 2013 and December 2018. The prevalence of different CMA results in pregnancies with normal US at the time of genetic testing ('low-risk pregnancies'), was compared with that in pregnancies with abnormal US findings ('high-risk pregnancies'). Medical records were searched in order to evaluate subsequent US follow-up and the outcome of pregnancies with a clinically relevant copy-number variant (CNV), i.e. a pathogenic or likely pathogenic CNV or a susceptibility locus for disease with > 10% penetrance, related to early-onset disease in the low-risk group.

RESULTS: In a cohort of 6431 low-risk pregnancies that underwent CMA, the prevalence of a clinically significant CNV related to early-onset disease was 1.1% (72/6431), which was significantly lower than the prevalence in high-risk pregnancies (4.9% (65/1326)). Of the low-risk pregnancies, 0.4% (27/6431) had a pathogenic or likely pathogenic CNV, and another 0.7% (45/6431) had a susceptibility locus with more than 10% penetrance. Follow-up of the low-risk pregnancies with a clinically significant early-onset CNV revealed that 31.9% (23/72) were terminated, while outcome data were missing in 26.4% (19/72). In 16.7% (12/72) of low-risk pregnancies, an US abnormality was discovered later on in gestation, after genetic testing had been performed.

CONCLUSION: Although the background risk of identifying a clinically significant early-onset abnormal CMA result in pregnancies with a low a-priori risk is lower than that observed in high-risk pregnancies, the risk is substantial and should be conveyed to all pregnant women. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Stern S, Hacohen N, Meiner V, et al. Universal chromosomal microarray analysis reveals high proportion of copy-number variants in low-risk pregnancies. Ultrasound Obstet Gynecol. 2021. PMID: 32202684. doi:10.1002/uog.22026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。